(NASDAQ: GPCR) Structure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Structure Therapeutics's earnings in 2025 is -$210,685,000.On average, 16 Wall Street analysts forecast GPCR's earnings for 2025 to be -$263,037,569, with the lowest GPCR earnings forecast at -$267,588,392, and the highest GPCR earnings forecast at -$256,120,318. On average, 16 Wall Street analysts forecast GPCR's earnings for 2026 to be -$321,979,829, with the lowest GPCR earnings forecast at -$399,598,666, and the highest GPCR earnings forecast at -$273,322,429.
In 2027, GPCR is forecast to generate -$357,640,078 in earnings, with the lowest earnings forecast at -$488,794,797 and the highest earnings forecast at -$303,903,960.